FindTrial
Sign In

YTS109

BIOLOGICAL2 trials

Sponsors

China Immunotech (Beijing) Biotechnology Co., Ltd., Institute of Hematology & Blood Diseases Hospital, China

Conditions

Anti-CD19 STAR T-cell TherapyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntiphospholipid SyndromeAutoimmune Hemolytic AnemiaFailure ≥3 Lines of TherapiesInflammatory MyopathySjogren's SyndromeSystemic Lupus Erythematosus

Phase 1

A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruitingNCT06770504
Institute of Hematology & Blood Diseases Hospital, ChinaAnti-CD19 STAR T-cell Therapy, Autoimmune Hemolytic Anemia, Failure ≥3 Lines of Therapies
Start: 2025-01-16End: 2026-12-30Target: 7Updated: 2025-01-13

Unknown Phase

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
RecruitingNCT06379646
China Immunotech (Beijing) Biotechnology Co., Ltd.Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antiphospholipid Syndrome, Inflammatory Myopathy +3
Start: 2024-04-24End: 2026-04-21Target: 6Updated: 2024-08-29

Related Papers

Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.
2025-08-272 citations